Skip to main content
Statusartikel

Influenzavaccination af onkologiske patienter

Influenzavirus.
Influenzavirus.

Anna Andreeva1, Anne-Cathrine Bareid Østby2 & Anders Mellemgaard2

11. nov. 2013
4 min.

Influenzavirus.

Summary

Influenza vaccination of cancer patients

Influenza infection adds to the morbidity and mortality in cancer patients. This paper reviews studies on the ability of adult cancer patients to develop a protective immunological response to influenza vaccination. The studies showed that patients undergoing chemotherapy were able to develop an immunological response and seroprotection. The ideal administration time in the course of a chemotherapy treatment was unclear, but the longest time from chemotherapy was preferred. Repeated vaccination may be beneficial. Influenza vaccination is safe, inexpensive and easily available.

Referencer

LITTERATUR

  1. Fiore AE, Shay DK, Broder K et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices. MMWR 2009;58:1-52.

  2. Gasparini R, Amicizia D, Lai PL et al. Effectiveness of adjuvanted seasonal influenza vaccines (Inflexal V and Fluad) in preventing hospitalization for influenza and pneumonia in the elderly: a matched case-control study. Hum Vaccin Immunother 2013;9:144-52.

  3. Kavanaugh DY, Carbone DP. Immunologic dysfunction in cancer. Hematol Oncol Clin North Am 1996;10:927-51.

  4. Finke J, Ferrone S, Frey A et al. Where have all the T cells gone? Immunol Today 1999;20:158-160.

  5. Griffiths RW, Elkord E, Gilham DE et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007;56:1743-53.

  6. Gigante M, Blasi A, Loverre A et al. Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anticancer vaccine. Mol Immunol 2009;46:893-901.

  7. Pardoll DM, Topalian SL. The role of CD4þ T cell responses in antitumor immunity. Curr Opin Immunol 1998;10:588-94.

  8. Cooksley CD, Avritscher EB, Bekele BN et al. Epidemiology and outcomes of
    serious influenza-related infections in the cancer population. Cancer 2005;104:618-28.

  9. Ring A, Marx G, Steer C et al. Poor uptake of influenza vaccinations in patients receiving cytotoxic chemotherapy. Int J Clin Pract 2003;57:542-3.

  10. Yee SS, Dutta PR, Solin LJ et al. Lack of compliance with national vaccination guidelines in oncology patients receiving radiation therapy. J Support Oncol 2010;8:28-34.

  11. Lulergue P, Mir O, Alexandre J et al. Low influenza vaccination rate among patients receiving chemotherapy for cancer. Ann Oncol 2008;1:1658.

  12. Coudeville L, Bailleux F, Riche B et al. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian random-effects model. BMC Med Res
    Methodol 2010;10:18.

  13. Craig C, Earle J. Influenza vaccination in elderly patients with advanced colorectal cancer. J Clin Oncol 2003;21:1161-6.

  14. Xu Y, Methuku N, Coimbatore P et al. Immunogenicity of an inactivated monovalent 2009 influenza A (H1N1) vaccine in patients who have cancer. Oncologist 2012;17:125-34.

  15. Hottinger AF, George AC, Bel M et al, H1N1 Study Group. A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients. Oncologist 2012;17:436-45.

  16. Lagler H, Tobudic S, Ramharter M et al. Pandemic whole-virion, Vero-cell-
    derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment:
    immunogenicity, tolerability, and acceptability during the pandemic situation. Vaccine 2012;30:6864-8.

  17. Rousseau B, Loulergue P, Mir O et al. Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study. Ann Oncol
    2012;23:450-7.

  18. Mackay HJ, McGee J, Villa D et al. Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on
    active systemic treatment. J Clin Virol 2011;50:212-6.

  19. de Lavallade H, Garland P, Sekine T et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host.
    Haematologica 2011;96:307-14.

  20. Nordøy T, Aaberge IS, Husebekk A et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol 2002;19:71-8.

  21. Pollyea DA, Brown JM, Horning SJ. Utility of influenza vaccination for oncology patients. J Clin Oncol 2010;28:2481-90.

  22. Ramanathan RK, Potter DM, Belani CP et al. Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patients. J Clin Oncol 2002;20:4313-8.

  23. Roman F, Vaman T, Gerlach B et al. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010;28:1740-5.

  24. Marra F, Young F, Richardson K et al. A meta-analysis of intradermal versus intramuscular influenza vaccines: immunogenicity and adverse events. Influenza Other Respi Viruses 2013;7:584-603.

  25. Keitel WA, Atmar RL, Nino D et al. Increasing doses of an inactivated influenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants. J Infect Dis 2008;198:1016-8.